Table 1: Baseline characteristics for Abiraterone and Enzalutamide patients.
|
|
Enzalutamide |
Abiraterone |
p values |
|
Number |
236 |
127 |
|
|
Median age (range) Years |
76 (57 - 93) |
76 (52 - 89) |
p = 0.310 |
|
Gleason prognostic group distribution: 1 2 3 4 5 Not recorded |
6% 6% 8% 12% 21% 47% |
8% 6% 4% 6% 14% 62% |
p = 0.576 p = 0.994 p = 0.136 p = 0.075 p = 0.091 p = 0.007 |
|
Previous lines of treatment 1 2 3 4 5 |
1% 32% 55% 10% 2% |
2% 35% 55% 8% |
p = 0.235 p = 0.622 p = 0.964 p = 0.485 |
|
Median starting PSA |
59 (0.03-9537) |
81 (2.1-1834) |
p = 0.364 |
|
Proportion chemotherapy-naïve |
79% |
89% |
p = 0.075 |